Jetty Overbeek

PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, Netherlands

Poster(s):

• (A-339) 2024 interim results from the VAC4EU post-authorisation safety study (PASS) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty®) in Europe
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (C-237) Assessing the Risk of Angioedema in Adult Sacubitril/Valsartan Users With Heart Failure: Results From a Post-Authorization Safety Study in Seven European Electronic Healthcare Databases
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• (A-338) Evaluating the Diagnostic Accuracy of Adverse Events of Special Interest Following Janssen COVID-19 Vaccine (JCOVDEN) Using the VAC4EU Validation Pipeline
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (SLC-037) Implementing and Validating an Algorithm for Identifying ATTR-CM patients in the PHARMO Data Network
  Tuesday, August 26, 2025

  12:15 PM - 1:15 PM ET

• (SLB-036) Investigating Potential Drug-Drug-Interactions Between Sacubitril/Valsartan and Statins and the Risk of Myotoxicity, Hepatotoxicity or Acute Pancreatitis: A Post-Authorisation Safety Study in 7 European Healthcare Databases
  Monday, August 25, 2025

  11:45 AM - 12:45 PM ET

• (B-276) Paternal Linkage in the PHARMO Data Network: Assessing the Impact of Paternal Drug Exposure on Child Health Outcomes
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET

• (SLC-053) Risk of Venous Thrombosis With Thrombocytopenia Syndrome After Vaccination With AZD1222: A European VAC4EU Post-Authorisation Safety Study
  Tuesday, August 26, 2025

  12:15 PM - 1:15 PM ET